A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
for
Non-Small Cell Lung Cancer, NSCLC,
Location: Boston MA, Westbury NY, New York NY, Washington D.C. DC,
Sponsor: Revolution Medicines, Inc.
Sex: All
Age: 18+
Code: NCT06162221
Phase1, Phase2, Recruiting
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
for
Recurrent Adult T-Cell Leukemia/Lymphoma,
Location: Columbus OH
Sponsor: John Reneau
Sex: All
Age: 18+
Code: NCT04848064
Phase1, Recruiting
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
for
Non Small Cell Lung Cancer, Triple Negative Breast Cancer,
Location: Boston MA, Buffalo NY, Orlando FL, Sarasota FL,
Sponsor: Compass Therapeutics
Sex: All
Age: 18+
Code: NCT06150664
Phase1, Recruiting
Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta
for
DLBCL - Diffuse Large B Cell Lymphoma
Location: Toronto
Sponsor: University Health Network, Toronto
Sex: All
Age: 18+
Code: NCT05950802
Phase1, Recruiting
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
for
Non-small Cell Lung Cancer,
Location: New Haven CT, Norwalk CT, New York NY, Montreal,